|Description||PSB 0739 is a highly potent, direct‐acting and reversible P2Y12 receptor antagonist (Ki = 24.9 nM). Unlike clopidogrel, it does not require bioactivation. P2Y12 receptors regulate CFA‐induced hyperalgesia and the local inflammatory response, and platelet P2Y12 receptors contribute to these effects in the chronic inflammation phase.|
|Purity||≥95% by HPLC|
|Synonyms||1-Amino-9,10-dihydro-9,10-dioxo-4-[[4-(phenylamino)-3-sulfophenyl]amino]-2-anthracenesulfonic acid sodium salt; PSB-0739; PSB 0739; PSB0739 sodium|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
The thiolactone form of Clopidogrel that could be an effective antiplatelet agent for behaving as an inhibitor of P2Y12 receptor.
PSB 1114, a β,γ‐difluoromethylene derivative of 4‐thio‐UTP, is a potent, selective P2Y2 agonist (EC50 = 0.134 μM),with >60-fold selectivity versus P2Y4 and P2Y6...
Prasugrel is a platelet inhibitor (IC50=1.8 μM) , as a third-generation thienopyridine.
The sodium salt of Suramin which is a P2 purinergic antagonist and has been also found to have the effect in blocking the G protein binds to GPCRs so that it wa...
AR-C 66096 tetrasodium salt
The sodium salt form of AR-C 66096, which has been found to be a P2Y12 receptor antagonist and could be probably used as an antithrombotic agent.
5-OMe-UDP trisodium salt
5-OMe-UDP trisodium salt is a P2Y6 agonist with EC50 value of 0.08 μM.
MRS 2690 is a potent P2Y14 receptor agonist (EC50 = 49 nM), with 7-fold higher potency than UDP-glucose.
Diquafosol tetrasodium, also referred to Diquas, is aP2Y2receptor agonist that is targeted to treat dry eye disease through rehydration of the ocular surface.